Lifevantage (NASDAQ:LFVN) Posts Quarterly Earnings Results, Misses Expectations By $0.01 EPS

Lifevantage (NASDAQ:LFVN) announced its quarterly earnings data on Thursday. The company reported $0.11 earnings per share for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.01), FiscalAI reports. Lifevantage had a return on equity of 21.63% and a net margin of 2.78%.The firm had revenue of $42.38 million during the quarter, compared to analysts’ expectations of $44.00 million.

Here are the key takeaways from Lifevantage’s conference call:

• Fourth-quarter revenue fell 23.1% year over year to $42.4 million, driven by fewer orders, lower average order values, weaker MindBody GLP-1 System sales, and macroeconomic pressure. Adjusted EBITDA declined to $2.7 million from $4.8 million.
• Management expects difficult year-over-year comparisons in fiscal 2027’s first and second quarters and is not providing formal guidance amid the recent CEO transition; it hopes new strategies can improve momentum in the second half of the fiscal year.
• New CEO Terrence Moorehead outlined priorities to strengthen the brand, improve consumer relevance and sales-force tools, upgrade digital and e-commerce capabilities, and enhance operational efficiency. Management emphasized LifeVantage’s differentiated science and historically strong gross margins, but acknowledged substantial execution work remains.
• The company ended fiscal 2026 with $14.9 million in cash and no debt, generated $10.2 million in operating cash flow, and retains access to a $5 million revolving credit facility.
• LifeVantage continued returning capital through approximately $2 million of fiscal 2026 share repurchases and initiated a $0.05 quarterly dividend; $58.5 million remains available under its share-repurchase authorization.

Lifevantage Trading Down 1.4%

Shares of LFVN opened at $6.36 on Friday. The firm has a fifty day simple moving average of $6.42 and a two-hundred day simple moving average of $5.84. The firm has a market cap of $80.24 million, a PE ratio of 15.90 and a beta of 0.72. Lifevantage has a 1-year low of $3.90 and a 1-year high of $14.28.

Lifevantage Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 15th. Shareholders of record on Tuesday, September 1st will be paid a dividend of $0.05 per share. The ex-dividend date is Tuesday, September 1st. This represents a $0.20 dividend on an annualized basis and a yield of 3.1%. Lifevantage’s payout ratio is currently 50.00%.

Wall Street Analyst Weigh In

LFVN has been the subject of a number of research analyst reports. Weiss Ratings reissued a “hold (c)” rating on shares of Lifevantage in a report on Friday, August 21st. Lake Street Capital increased their price objective on Lifevantage from $5.00 to $6.00 and gave the company a “hold” rating in a research report on Friday. Two equities research analysts have rated the stock with a Hold rating, According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $5.50.

Institutional Trading of Lifevantage

Large investors have recently modified their holdings of the company. JPMorgan Chase & Co. increased its position in Lifevantage by 870.2% during the second quarter. JPMorgan Chase & Co. now owns 5,016 shares of the company’s stock valued at $66,000 after acquiring an additional 4,499 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in shares of Lifevantage during the 2nd quarter valued at about $76,000. BNP Paribas Financial Markets grew its stake in shares of Lifevantage by 2,555.8% during the 2nd quarter. BNP Paribas Financial Markets now owns 6,135 shares of the company’s stock valued at $80,000 after purchasing an additional 5,904 shares during the period. Cubist Systematic Strategies LLC bought a new stake in shares of Lifevantage during the 1st quarter valued at about $97,000. Finally, New York State Common Retirement Fund purchased a new stake in shares of Lifevantage during the 2nd quarter valued at about $102,000. Institutional investors own 35.32% of the company’s stock.

Lifevantage Company Profile

LifeVantage Corporation is a publicly traded company that develops, markets and distributes nutritional supplements, skincare products and weight-management solutions through a direct-selling business model. The company’s flagship offering, Protandim®, is formulated to activate the Nrf2 pathway, which is associated with cellular defense processes. LifeVantage also markets the PhysIQ® line for metabolism and body composition support and the TrueScience® skincare regimen, targeting a range of health and wellness needs.

Founded in 1999 and headquartered in Sandy, Utah, LifeVantage combines research in nutrigenomics with a network of independent distributors to bring its products to market.